LEAFLET

LEVO-25

Levomepromazine Tablets BP 25 mg

Composition :
Each uncoated tablet contains:
Levomepromazine Maleate BP .... 25 mg
Excipients ..... q.s.

Action :
Levo-25 is a neuroleptic with indications in psychiatry , and in general medicine particularly in terminal illness. Clinically it is more sedative and more potent that chlorpromazine in the management of psychotic conditions and in the relief of chronic severe pain.
Levomepromazine resembles chlorpromazine and promethazine in the pattern of its pharmacology. It possess analgesic, anti-emetic, anti-histamine and anti-adrenaline activity and exhibits a strong sedative effect.

Pharmacokinetic Properties :
Maximum serum concentrations are achieved in the 2 to 3 hours depending on the route of administration. Excretion is slow, with half- life of about 30 hours. It is Eliminated via urine and faeces.

Pharmacodynamic properties :
Levomepromazine resembles chlorpromazine and promethazine in the pattern of its pharmacology. It possesses anti-emetic, antihistamine and anti-adrenaline activity and exhibits a strong sedative effect.

Indications :
It is indicated in the management of terminal pain and accompanying restlessness or distress.

Contraindications :
Hypersensivity to levomepromazine or any of the ingredients.Safety in pregnancy has not been- established. There are no absolute contraindications to the use of Levomepromazine in terminal care. The medicine should be avoided or used with caution in patients with liver dysfunction or cardiac disease.

Dosage & Administration :
Ambulant Patients: Initially the total daily dose should not exceed 25-50 mg usually divided into three doses. A larger portion of the dosage may be taken at bedtime to minimize diurnal sedation.

Bed Patients : Initially the total dosage may be 100 mg to 200 mg usually divided into three dose gradually increased to 1 g daily if necessary.

Children: Children are very susceptible to the hyposensitive and soporific effects of levomepromazine . It is advised that a total daily oral dose of 40 mg should not be exceeded.

Special precaution & warning : The drug should be avoided or used with caution in patients with liver dysfunction or cardiac disease . The hyposensitive effects of Levomepromazine tablets should be taken into account when it is administered to patients with cardiac disease. It may cause drowsiness, disorientation, confusion or excessive hypotension. Patient receiving Levomepromazine Tablet should not drive or operate machinery.

Adverse effect :
Dry mouth is encountered infrequently.
Hypotension may occur, especially in elderly patients.
Jaundice is arare side effect.
Heptocellular, cholestatic and mixed liver injury have been reported.

Ovedosage :
Symptoms of levomepromazine overdosage include drowsiness or loss of consciousness, hypotension, tachycardia, ECG changes may occur. If the patient is seen sufficiently soon (up to 6 hours) after ingestion of toxic dose, gastric levage may be attempted.
Venticular or supraventricular tachy-arrhythmias usually respond to restoration of normal body temperature and correction of circulatory or metabolic disturb persistant or life-threatening appropriate anti-arrhythmic therapy may be considered. Avoid lidocaine and as far as possible long acting anti-arrhythmic drugs.

STORAGE : Store under normal storage conditions (15°C to 30°C)
Protect from light.

Keep all medicines out of reach of children.

PRESENTATION : Blister pack of 2 x 10 Tablets, 10 x 10 Tablets.
Jar pack of 1000 Tablets.

IN67/01/01

Manufactured in India by:
AGOG PHARMA LTD.
Plot No. 33, Sector II, Tha Vasai Taluka Indl. Co-op. Estate Ltd., Vasai (E), Dist. Thane. INDIA.